Profilin-1 (Ambrosia artemisiifolia) (Amb a 8)

Amb a 8 is a minor allergen derived from short ragweed (Ambrosia artemisiifolia) and is a member of the profilin family of proteins [1, 2]. Biologically, it functions as a highly conserved actin-binding protein that regulates the assembly and disassembly of the actin cytoskeleton by sequestering monomeric G-actin [1, 2, 5]. In the context of human health, Amb a 8 is recognized by the immune system of approximately 20% of ragweed-allergic individuals, where it triggers IgE-mediated hypersensitivity reactions such as allergic rhinitis and asthma [3, 6]. Due to its high structural similarity with profilins in other pollens and plant-derived foods, it acts as a pan-allergen, contributing significantly to cross-reactivity and the development of Pollen-Food Allergy Syndrome [1, 3, 7]. For therapeutic purposes, Amb a 8 is a component of ragweed allergen immunotherapy (AIT), which aims to desensitize patients by inducing T-cell tolerance and shifting the antibody profile from IgE toward protective IgG4 [11, 12]. Clinical diagnostic testing for Amb a 8-specific IgE is increasingly used in precision medicine to distinguish primary ragweed sensitization from secondary cross-reactivity [3, 10].

Other names

Ragweed profilinAmb a 8.0101Amb a 8.0102

Allergen immunotherapy (AIT) utilizes the Amb a 8 protein within ragweed extracts to induce T-cell tolerance and promote an immune shift from IgE-mediated hypersensitivity to a protective IgG4-mediated response. Biologic agents like Omalizumab can be used as an adjunct to bind and neutralize the circulating IgE antibodies that target this molecule, thereby reducing the risk of clinical allergic reactions during desensitization.